Rare Disease

Latest News

Phase 3 Study of Amgen Biosimilar to Eculizumab Meets Primary End Points
Phase 3 Study of Amgen Biosimilar to Eculizumab Meets Primary End Points

August 24th 2022

Eculizumab is used to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare bone marrow disorder in which expansion of certain hematopoietic cells that lack a key protein cause the destruction of red blood cells, or hemolysis.

Opinion: Biosimilars Can Aid in Post–COVID-19 Health Care Financial Recovery
Opinion: Biosimilars Can Aid in Post–COVID-19 Health Care Financial Recovery

June 19th 2021

Medicines for Europe Panel Targets Waste in Health Care, Need for Education
Medicines for Europe Panel Targets Inefficiencies, Need for Education

May 28th 2021

Samsung Bioepis Wins Biosimilar Package Design Awards
Samsung Bioepis Racks Up More Awards for Its Biosimilar Packaging

April 24th 2021

Poll: What Is the Best Way to Improve Biosimilar Access?
Poll: What Is the Best Way to Improve Biosimilar Access?

April 14th 2021

More News

© 2023 MJH Life Sciences

All rights reserved.